{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:24:21Z","timestamp":1787084661289,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R00EB030013-03"],"award-info":[{"award-number":["R00EB030013-03"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2010054"],"award-info":[{"award-number":["W81XWH2010054"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2010054"],"award-info":[{"award-number":["W81XWH2010054"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effective and safe vaccines are invaluable tools in the arsenal to fight infectious diseases. The rapid spreading of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 pandemic has highlighted the need to develop methods for rapid and efficient vaccine development. DNA origami nanoparticles (DNA-NPs) presenting multiple antigens in prescribed nanoscale patterns have recently emerged as a safe, efficient, and easily scalable alternative for rational design of vaccines. Here, we are leveraging the unique properties of these DNA-NPs and demonstrate that precisely patterning ten copies of a reconstituted trimer of the receptor binding domain (RBD) of SARS-CoV-2 along with CpG adjuvants on the DNA-NPs is able to elicit a robust protective immunity against SARS-CoV-2 in a mouse model. Our results demonstrate the potential of our DNA-NP-based approach for developing safe and effective nanovaccines against infectious diseases with prolonged antibody response and effective protection in the context of a viral challenge.<\/jats:p>","DOI":"10.1038\/s42003-023-04689-2","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T05:03:06Z","timestamp":1679547786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response"],"prefix":"10.1038","volume":"6","author":[{"given":"Esra","family":"Oktay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhang","family":"Alem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divita","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor L.","family":"Medintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-4416","authenticated-orcid":false,"given":"Aarthi","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-3770","authenticated-orcid":false,"given":"Remi","family":"Veneziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"4689_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola, M. et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int. J. Surg. 78, 185\u2013193 (2020).","journal-title":"Int. J. Surg."},{"key":"4689_CR2","unstructured":"W. H. O. Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int."},{"key":"4689_CR3","doi-asserted-by":"publisher","unstructured":"da Costa, V. G., Moreli, M. L. & Saivish, M. V. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Arch. Virol. 1\u201310 https:\/\/doi.org\/10.1007\/s00705-020-04628-0. (2020)","DOI":"10.1007\/s00705-020-04628-0"},{"key":"4689_CR4","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 109, 102434 (2020).","DOI":"10.1016\/j.jaut.2020.102434"},{"key":"4689_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","volume":"27","author":"Y-D Li","year":"2020","unstructured":"Li, Y.-D. et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J. Biomed. Sci. 27, 104 (2020).","journal-title":"J. Biomed. Sci."},{"key":"4689_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00369-6","volume":"6","author":"FX Heinz","year":"2021","unstructured":"Heinz, F. X. & Stiasny, K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. npj Vaccines 6, 104 (2021).","journal-title":"npj Vaccines"},{"key":"4689_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4689_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4689_CR9","doi-asserted-by":"publisher","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-021-00592-1. (2021)","DOI":"10.1038\/s41577-021-00592-1"},{"key":"4689_CR10","unstructured":"Commissioner, O. of the. Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted (2022)."},{"key":"4689_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-021-00360-1","volume":"8","author":"X-L Peng","year":"2021","unstructured":"Peng, X.-L. et al. Advances in the design and development of SARS-CoV-2 vaccines. Military Med. Res. 8, 67 (2021).","journal-title":"Military Med. Res."},{"key":"4689_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vaccines4020012","volume":"4","author":"A Vartak","year":"2016","unstructured":"Vartak, A. & Sucheck, S. J. Recent Advances in Subunit Vaccine Carriers. Vaccines (Basel) 4, 12 (2016).","journal-title":"Vaccines (Basel)"},{"key":"4689_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4155\/tde.11.68","volume":"2","author":"C Foged","year":"2011","unstructured":"Foged, C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther. Deliv. 2, 1057\u20131077 (2011).","journal-title":"Ther. Deliv."},{"key":"4689_CR14","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.1021\/acsnano.0c04006","volume":"14","author":"G Chauhan","year":"2020","unstructured":"Chauhan, G. et al. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano 14, 7760\u20137782 (2020).","journal-title":"ACS Nano"},{"key":"4689_CR15","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"R Pati","year":"2018","unstructured":"Pati, R., Shevtsov, M. & Sonawane, A. Nanoparticle Vaccines Against Infectious Diseases. Front. Immunol. 9, 2224 (2018).","journal-title":"Front. Immunol."},{"key":"4689_CR16","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.mtcomm.2020.101692","volume":"25","author":"R Augustine","year":"2020","unstructured":"Augustine, R. et al. Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. Mater. Today Commun. 25, 101692 (2020).","journal-title":"Mater. Today Commun."},{"key":"4689_CR17","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.ebiom.2021.103699","volume":"74","author":"MN Vu","year":"2021","unstructured":"Vu, M. N., Kelly, H. G., Kent, S. J. & Wheatley, A. K. Current and future nanoparticle vaccines for COVID-19. EBioMed. 74, 103699 (2021).","journal-title":"EBioMed."},{"key":"4689_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1021\/acscentsci.1c00216","volume":"7","author":"Y Valdes-Balbin","year":"2021","unstructured":"Valdes-Balbin, Y. et al. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Cent. Sci. 7, 757\u2013767 (2021).","journal-title":"ACS Cent. Sci."},{"key":"4689_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"4689_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","volume":"30","author":"W Tai","year":"2020","unstructured":"Tai, W. et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 30, 932\u2013935 (2020).","journal-title":"Cell Res."},{"key":"4689_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00393-6","volume":"6","author":"H Kleanthous","year":"2021","unstructured":"Kleanthous, H. et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines 6, 128 (2021).","journal-title":"npj Vaccines"},{"key":"4689_CR22","doi-asserted-by":"publisher","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","volume":"5","author":"L Premkumar","year":"2020","unstructured":"Premkumar, L. et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).","journal-title":"Sci. Immunol."},{"key":"4689_CR23","doi-asserted-by":"publisher","first-page":"104043","DOI":"10.1016\/j.isci.2022.104043","volume":"25","author":"Q Liang","year":"2022","unstructured":"Liang, Q. et al. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. iScience 25, 104043 (2022).","journal-title":"iScience"},{"key":"4689_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","volume":"6","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Sig. Transduct. Target Ther. 6, 233 (2021).","journal-title":"Sig. Transduct. Target Ther."},{"key":"4689_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","volume":"588","author":"DJ Benton","year":"2020","unstructured":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327\u2013330 (2020).","journal-title":"Nature"},{"key":"4689_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"4689_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"4689_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23942-y","volume":"12","author":"NK Routhu","year":"2021","unstructured":"Routhu, N. K. et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat. Commun. 12, 3587 (2021).","journal-title":"Nat. Commun."},{"key":"4689_CR29","first-page":"100140","volume":"2","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. Innovation 2, 100140 (2021).","journal-title":"Innovation"},{"key":"4689_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74949-2","volume":"10","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci. Rep. 10, 18149 (2020).","journal-title":"Sci. Rep."},{"key":"4689_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733.e11 (2020).","journal-title":"Cell"},{"key":"4689_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","volume":"299","author":"AN Ilinskaya","year":"2016","unstructured":"Ilinskaya, A. N. & Dobrovolskaia, M. A. Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol. Appl. Pharmacol. 299, 70\u201377 (2016).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"4689_CR33","doi-asserted-by":"publisher","first-page":"20200067","DOI":"10.1002\/VIW.20200067","volume":"2","author":"D Zheng","year":"2021","unstructured":"Zheng, D., Yang, K. & Nie, Z. Engineering heterogeneity of precision nanoparticles for biomedical delivery and therapy. VIEW 2, 20200067 (2021).","journal-title":"VIEW"},{"key":"4689_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-biophys-052118-115259","volume":"48","author":"E-C Wamhoff","year":"2019","unstructured":"Wamhoff, E.-C. et al. Programming Structured DNA Assemblies to Probe Biophysical Processes. Annu. Rev. Biophys. 48, 395\u2013419 (2019).","journal-title":"Annu. Rev. Biophys."},{"key":"4689_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature04586","volume":"440","author":"PWK Rothemund","year":"2006","unstructured":"Rothemund, P. W. K. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297\u2013302 (2006).","journal-title":"Nature"},{"key":"4689_CR36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1126\/science.aaf4388","volume":"352","author":"R Veneziano","year":"2016","unstructured":"Veneziano, R. et al. Designer nanoscale DNA assemblies programmed from the top down. Science 352, 1534\u20131534 (2016).","journal-title":"Science"},{"key":"4689_CR37","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","volume":"15","author":"R Veneziano","year":"2020","unstructured":"Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716\u2013723 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"4689_CR38","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1039\/c1cs15212b","volume":"40","author":"B Sacc\u00e0","year":"2011","unstructured":"Sacc\u00e0, B. & Niemeyer, C. M. Functionalization of DNA nanostructures with proteins. Chem. Soc. Rev. 40, 5910 (2011).","journal-title":"Chem. Soc. Rev."},{"key":"4689_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1021\/acsnano.8b05340","volume":"13","author":"Z Shen","year":"2019","unstructured":"Shen, Z., Ye, H., Yi, X. & Li, Y. Membrane Wrapping Efficiency of Elastic Nanoparticles during Endocytosis: Size and Shape Matter. ACS Nano 13, 215\u2013228 (2019).","journal-title":"ACS Nano"},{"key":"4689_CR40","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1039\/C9NR08958F","volume":"12","author":"P Lung","year":"2020","unstructured":"Lung, P., Yang, J. & Li, Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale 12, 5746\u20135763 (2020).","journal-title":"Nanoscale"},{"key":"4689_CR41","doi-asserted-by":"publisher","first-page":"607945","DOI":"10.3389\/fimmu.2020.607945","volume":"11","author":"MV Baranov","year":"2021","unstructured":"Baranov, M. V., Kumar, M., Sacanna, S., Thutupalli, S. & van den Bogaart, G. Modulation of Immune Responses by Particle Size and Shape. Front. Immunol. 11, 607945 (2021).","journal-title":"Front. Immunol."},{"key":"4689_CR42","doi-asserted-by":"publisher","first-page":"17247","DOI":"10.1073\/pnas.1305000110","volume":"110","author":"R Agarwal","year":"2013","unstructured":"Agarwal, R. et al. Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc. Natl. Acad. Sci. USA 110, 17247\u201317252 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4689_CR43","doi-asserted-by":"publisher","first-page":"2108063","DOI":"10.1002\/smll.202108063","volume":"18","author":"CR Lucas","year":"2022","unstructured":"Lucas, C. R. et al. DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small 18, 2108063 (2022).","journal-title":"Small"},{"key":"4689_CR44","doi-asserted-by":"publisher","unstructured":"Du, R. R. et al. Innate Immune Stimulation Using 3D Wireframe DNA Origami. ACS Nano acsnano.2c06275 https:\/\/doi.org\/10.1021\/acsnano.2c06275. (2022)","DOI":"10.1021\/acsnano.2c06275"},{"key":"4689_CR45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"4689_CR46","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/eji.200737984","volume":"38","author":"V Manolova","year":"2008","unstructured":"Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404\u20131413 (2008).","journal-title":"Eur. J. Immunol."},{"key":"4689_CR47","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","volume":"25","author":"ST Reddy","year":"2007","unstructured":"Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159\u20131164 (2007).","journal-title":"Nat. Biotechnol."},{"key":"4689_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24677-5","volume":"8","author":"R Veneziano","year":"2018","unstructured":"Veneziano, R. et al. In vitro synthesis of gene-length single-stranded DNA. Sci. Rep. 8, 6548 (2018).","journal-title":"Sci. Rep."},{"key":"4689_CR49","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.3390\/molecules25153386","volume":"25","author":"J Bush","year":"2020","unstructured":"Bush, J. et al. Synthesis of DNA Origami Scaffolds: Current and Emerging Strategies. Molecules 25, 3386 (2020).","journal-title":"Molecules"},{"key":"4689_CR50","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/sj.ejhg.5201226","volume":"12","author":"F Pellestor","year":"2004","unstructured":"Pellestor, F. & Paulasova, P. The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics. Eur. J. Hum. Genet. 12, 694\u2013700 (2004).","journal-title":"Eur. J. Hum. Genet."},{"key":"4689_CR51","unstructured":"CpG 1018 | toll-like receptor 9 (TLR9) agonist adjuvant | Dynavax Technologies. https:\/\/www.dynavax.com\/science\/cpg-1018\/."},{"key":"4689_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77077-z","volume":"10","author":"T-Y Kuo","year":"2020","unstructured":"Kuo, T.-Y. et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci. Rep. 10, 20085 (2020).","journal-title":"Sci. Rep."},{"key":"4689_CR53","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","volume":"9","author":"S-M Hsieh","year":"2021","unstructured":"Hsieh, S.-M. et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet. Resp. Med. 9, 1396\u20131406 (2021).","journal-title":"Lancet. Resp. Med."},{"key":"4689_CR54","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1021\/ja4000728","volume":"135","author":"X Wei","year":"2013","unstructured":"Wei, X., Nangreave, J., Jiang, S., Yan, H. & Liu, Y. Mapping the Thermal Behavior of DNA Origami Nanostructures. J. Am. Chem. Soc. 135, 6165\u20136176 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"4689_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41570-021-00251-y","volume":"5","author":"AR Chandrasekaran","year":"2021","unstructured":"Chandrasekaran, A. R. Nuclease resistance of DNA nanostructures. Nat. Rev. Chem. 5, 225\u2013239 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"4689_CR56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41421-021-00320-y","volume":"7","author":"X Pan","year":"2021","unstructured":"Pan, X. et al. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discov. 7, 82 (2021).","journal-title":"Cell Discov."},{"key":"4689_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41421-021-00302-0","volume":"7","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. Cell Discov. 7, 65 (2021).","journal-title":"Cell Discov."},{"key":"4689_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"4689_CR59","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"4689_CR60","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3389\/fimmu.2020.585354","volume":"11","author":"O Sharma","year":"2020","unstructured":"Sharma, O., Sultan, A. A., Ding, H. & Triggle, C. R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 11, 2413 (2020).","journal-title":"Front. Immunol."},{"key":"4689_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis, N. C., L\u00f3pez-Cort\u00e9s, A., Gonz\u00e1lez, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines 6, 28 (2021).","journal-title":"npj Vaccines"},{"key":"4689_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20247-4","volume":"12","author":"EHY Lau","year":"2021","unstructured":"Lau, E. H. Y. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 12, 63 (2021).","journal-title":"Nat. Commun."},{"key":"4689_CR63","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/infdis\/jiab140","volume":"223","author":"A Haymond","year":"2021","unstructured":"Haymond, A. et al. Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days. J. Infect. Dis. 223, 1677\u20131680 (2021).","journal-title":"J. Infect. Dis."},{"key":"4689_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).","journal-title":"Nat. Commun."},{"key":"4689_CR65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"4689_CR66","doi-asserted-by":"publisher","first-page":"e1009195","DOI":"10.1371\/journal.ppat.1009195","volume":"17","author":"CK Yinda","year":"2021","unstructured":"Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog 17, e1009195 (2021).","journal-title":"PLoS Pathog"},{"key":"4689_CR67","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.cmi.2020.03.025","volume":"26","author":"MR Capobianchi","year":"2020","unstructured":"Capobianchi, M. R. et al. Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy. Clin. Microbiol. Infect. 26, 954\u2013956 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"4689_CR68","doi-asserted-by":"publisher","unstructured":"Lien, C.-E. et al. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. Clin. Infect. Dis. ciab711 https:\/\/doi.org\/10.1093\/cid\/ciab711. (2021)","DOI":"10.1093\/cid\/ciab711"},{"key":"4689_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41421-022-00380-8","volume":"8","author":"J Xue","year":"2022","unstructured":"Xue, J. et al. Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant. Cell Discov. 8, 15 (2022).","journal-title":"Cell Discov."},{"key":"4689_CR70","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3390\/vaccines10122038","volume":"10","author":"M Golshani","year":"2022","unstructured":"Golshani, M. et al. SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers. Vaccines 10, 2038 (2022).","journal-title":"Vaccines"},{"key":"4689_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.644","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. Clin.Transl. Med. 11, e644 (2021).","journal-title":"Clin.Transl. Med."},{"key":"4689_CR72","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/jps.10166","volume":"91","author":"CT Johnston","year":"2002","unstructured":"Johnston, C. T., Wang, S. & Hem, S. L. Measuring the surface area of aluminum hydroxide adjuvant. J. Pharm. Sci. 91, 1702\u20131706 (2002).","journal-title":"J. Pharm. Sci."},{"key":"4689_CR73","doi-asserted-by":"publisher","first-page":"eabj6538","DOI":"10.1126\/sciadv.abj6538","volume":"7","author":"KA Rodrigues","year":"2021","unstructured":"Rodrigues, K. A. et al. Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. Sci. Adv. 7, eabj6538 (2021).","journal-title":"Sci. Adv."},{"key":"4689_CR74","unstructured":"\u201cFour Parameter Logistic Curve\u201d online data analysis tool, MyAssays Ltd., 1st December 2022, http:\/\/www.myassays.com\/four-parameter-logistic-curve.assay."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04689-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T06:02:38Z","timestamp":1679551358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4689"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04689-2","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Veneziano is listed as an inventor on submitted patents related to this work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"308"}}